不活化インフルエンザワクチンのグローバル市場インサイト・予測（～2028年）

• 英文タイトル：Global Inactivated Influenza Vaccine Market Insights, Forecast to 2028

• レポートコード：QY2203B13531 • 出版社/出版日：QYResearch / 2022年3月 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥686,000 (USD4,900)	▷ お問い合わせ
Multi User	￥1,029,000 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,372,000 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

新型コロナウイルス感染症のパンデミックにより、世界の不活化インフルエンザワクチンの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に不活化インフルエンザワクチンの世界市場のxxx％を占める「3価インフルエンザワクチン」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「小児」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国の不活化インフルエンザワクチンの市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの不活化インフルエンザワクチン市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの不活化インフルエンザワクチン市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 不活化インフルエンザワクチンのグローバル主要メーカーには、CSL Limited、GSK、Sanofi Pasteur、Viatris、Hualan Biological、AstraZeneca、Sinovac Biotech、Aleph Biomedical、Abbott Laboratories、Novartis Internationalなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 不活化インフルエンザワクチン市場は、種類と用途によって区分されます。世界の不活化インフルエンザワクチン市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 3価インフルエンザワクチン、4価インフルエンザワクチン 【用途別セグメント】 小児、思春期、成人、高齢者 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 不活化インフルエンザワクチン製品概要 - 種類別市場（3価インフルエンザワクチン、4価インフルエンザワクチン） - 用途別市場（小児、思春期、成人、高齢者） - 調査の目的 ・エグゼクティブサマリー - 世界の不活化インフルエンザワクチン販売量予測2017-2028 - 世界の不活化インフルエンザワクチン売上予測2017-2028 - 不活化インフルエンザワクチンの地域別販売量 - 不活化インフルエンザワクチンの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別不活化インフルエンザワクチン販売量 - 主要メーカー別不活化インフルエンザワクチン売上 - 主要メーカー別不活化インフルエンザワクチン価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（3価インフルエンザワクチン、4価インフルエンザワクチン） - 不活化インフルエンザワクチンの種類別販売量 - 不活化インフルエンザワクチンの種類別売上 - 不活化インフルエンザワクチンの種類別価格 ・用途別市場規模（小児、思春期、成人、高齢者） - 不活化インフルエンザワクチンの用途別販売量 - 不活化インフルエンザワクチンの用途別売上 - 不活化インフルエンザワクチンの用途別価格 ・北米市場 - 北米の不活化インフルエンザワクチン市場規模（種類別、用途別） - 主要国別の不活化インフルエンザワクチン市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの不活化インフルエンザワクチン市場規模（種類別、用途別） - 主要国別の不活化インフルエンザワクチン市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の不活化インフルエンザワクチン市場規模（種類別、用途別） - 主要国別の不活化インフルエンザワクチン市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の不活化インフルエンザワクチン市場規模（種類別、用途別） - 主要国別の不活化インフルエンザワクチン市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの不活化インフルエンザワクチン市場規模（種類別、用途別） - 主要国別の不活化インフルエンザワクチン市場規模（トルコ、サウジアラビア） ・企業情報 CSL Limited、GSK、Sanofi Pasteur、Viatris、Hualan Biological、AstraZeneca、Sinovac Biotech、Aleph Biomedical、Abbott Laboratories、Novartis International ・産業チェーン及び販売チャネル分析 - 不活化インフルエンザワクチンの産業チェーン分析 - 不活化インフルエンザワクチンの原材料 - 不活化インフルエンザワクチンの生産プロセス - 不活化インフルエンザワクチンの販売及びマーケティング - 不活化インフルエンザワクチンの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 不活化インフルエンザワクチンの産業動向 - 不活化インフルエンザワクチンのマーケットドライバー - 不活化インフルエンザワクチンの課題 - 不活化インフルエンザワクチンの阻害要因 ・主な調査結果

Market Analysis and Insights: Global Inactivated Influenza Vaccine Market
Due to the COVID-19 pandemic, the global Inactivated Influenza Vaccine market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Trivalent Influenza Vaccine accounting for % of the Inactivated Influenza Vaccine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Children segment is altered to an % CAGR throughout this forecast period.
China Inactivated Influenza Vaccine market size is valued at US$ million in 2021, while the US and Europe Inactivated Influenza Vaccine are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Inactivated Influenza Vaccine landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Inactivated Influenza Vaccine include CSL Limited, GSK, Sanofi Pasteur, Viatris, Hualan Biological, AstraZeneca, Sinovac Biotech, Aleph Biomedical and Abbott Laboratories and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Inactivated Influenza Vaccine Scope and Segment
Inactivated Influenza Vaccine market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Inactivated Influenza Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Trivalent Influenza Vaccine
Quadrivalent Influenza Vaccine
Segment by Application
Children
Adolescence
Adults
Elderly
By Company
CSL Limited
GSK
Sanofi Pasteur
Viatris
Hualan Biological
AstraZeneca
Sinovac Biotech
Aleph Biomedical
Abbott Laboratories
Novartis International
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

レポート目次

---

1 Study Coverage
1.1 Inactivated Influenza Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Inactivated Influenza Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Trivalent Influenza Vaccine
1.2.3 Quadrivalent Influenza Vaccine
1.3 Market by Application
1.3.1 Global Inactivated Influenza Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Children
1.3.3 Adolescence
1.3.4 Adults
1.3.5 Elderly
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Inactivated Influenza Vaccine Sales Estimates and Forecasts 2017-2028
2.2 Global Inactivated Influenza Vaccine Revenue Estimates and Forecasts 2017-2028
2.3 Global Inactivated Influenza Vaccine Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Inactivated Influenza Vaccine Sales by Region
2.4.1 Global Inactivated Influenza Vaccine Sales by Region (2017-2022)
2.4.2 Global Sales Inactivated Influenza Vaccine by Region (2023-2028)
2.5 Global Inactivated Influenza Vaccine Revenue by Region
2.5.1 Global Inactivated Influenza Vaccine Revenue by Region (2017-2022)
2.5.2 Global Inactivated Influenza Vaccine Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Inactivated Influenza Vaccine Sales by Manufacturers
3.1.1 Global Top Inactivated Influenza Vaccine Manufacturers by Sales (2017-2022)
3.1.2 Global Inactivated Influenza Vaccine Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Inactivated Influenza Vaccine in 2021
3.2 Global Inactivated Influenza Vaccine Revenue by Manufacturers
3.2.1 Global Inactivated Influenza Vaccine Revenue by Manufacturers (2017-2022)
3.2.2 Global Inactivated Influenza Vaccine Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Inactivated Influenza Vaccine Revenue in 2021
3.3 Global Inactivated Influenza Vaccine Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Inactivated Influenza Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Inactivated Influenza Vaccine Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Inactivated Influenza Vaccine Sales by Type
4.1.1 Global Inactivated Influenza Vaccine Historical Sales by Type (2017-2022)
4.1.2 Global Inactivated Influenza Vaccine Forecasted Sales by Type (2023-2028)
4.1.3 Global Inactivated Influenza Vaccine Sales Market Share by Type (2017-2028)
4.2 Global Inactivated Influenza Vaccine Revenue by Type
4.2.1 Global Inactivated Influenza Vaccine Historical Revenue by Type (2017-2022)
4.2.2 Global Inactivated Influenza Vaccine Forecasted Revenue by Type (2023-2028)
4.2.3 Global Inactivated Influenza Vaccine Revenue Market Share by Type (2017-2028)
4.3 Global Inactivated Influenza Vaccine Price by Type
4.3.1 Global Inactivated Influenza Vaccine Price by Type (2017-2022)
4.3.2 Global Inactivated Influenza Vaccine Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Inactivated Influenza Vaccine Sales by Application
5.1.1 Global Inactivated Influenza Vaccine Historical Sales by Application (2017-2022)
5.1.2 Global Inactivated Influenza Vaccine Forecasted Sales by Application (2023-2028)
5.1.3 Global Inactivated Influenza Vaccine Sales Market Share by Application (2017-2028)
5.2 Global Inactivated Influenza Vaccine Revenue by Application
5.2.1 Global Inactivated Influenza Vaccine Historical Revenue by Application (2017-2022)
5.2.2 Global Inactivated Influenza Vaccine Forecasted Revenue by Application (2023-2028)
5.2.3 Global Inactivated Influenza Vaccine Revenue Market Share by Application (2017-2028)
5.3 Global Inactivated Influenza Vaccine Price by Application
5.3.1 Global Inactivated Influenza Vaccine Price by Application (2017-2022)
5.3.2 Global Inactivated Influenza Vaccine Price Forecast by Application (2023-2028)
6 North America
6.1 North America Inactivated Influenza Vaccine Market Size by Type
6.1.1 North America Inactivated Influenza Vaccine Sales by Type (2017-2028)
6.1.2 North America Inactivated Influenza Vaccine Revenue by Type (2017-2028)
6.2 North America Inactivated Influenza Vaccine Market Size by Application
6.2.1 North America Inactivated Influenza Vaccine Sales by Application (2017-2028)
6.2.2 North America Inactivated Influenza Vaccine Revenue by Application (2017-2028)
6.3 North America Inactivated Influenza Vaccine Market Size by Country
6.3.1 North America Inactivated Influenza Vaccine Sales by Country (2017-2028)
6.3.2 North America Inactivated Influenza Vaccine Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Inactivated Influenza Vaccine Market Size by Type
7.1.1 Europe Inactivated Influenza Vaccine Sales by Type (2017-2028)
7.1.2 Europe Inactivated Influenza Vaccine Revenue by Type (2017-2028)
7.2 Europe Inactivated Influenza Vaccine Market Size by Application
7.2.1 Europe Inactivated Influenza Vaccine Sales by Application (2017-2028)
7.2.2 Europe Inactivated Influenza Vaccine Revenue by Application (2017-2028)
7.3 Europe Inactivated Influenza Vaccine Market Size by Country
7.3.1 Europe Inactivated Influenza Vaccine Sales by Country (2017-2028)
7.3.2 Europe Inactivated Influenza Vaccine Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Inactivated Influenza Vaccine Market Size by Type
8.1.1 Asia Pacific Inactivated Influenza Vaccine Sales by Type (2017-2028)
8.1.2 Asia Pacific Inactivated Influenza Vaccine Revenue by Type (2017-2028)
8.2 Asia Pacific Inactivated Influenza Vaccine Market Size by Application
8.2.1 Asia Pacific Inactivated Influenza Vaccine Sales by Application (2017-2028)
8.2.2 Asia Pacific Inactivated Influenza Vaccine Revenue by Application (2017-2028)
8.3 Asia Pacific Inactivated Influenza Vaccine Market Size by Region
8.3.1 Asia Pacific Inactivated Influenza Vaccine Sales by Region (2017-2028)
8.3.2 Asia Pacific Inactivated Influenza Vaccine Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Inactivated Influenza Vaccine Market Size by Type
9.1.1 Latin America Inactivated Influenza Vaccine Sales by Type (2017-2028)
9.1.2 Latin America Inactivated Influenza Vaccine Revenue by Type (2017-2028)
9.2 Latin America Inactivated Influenza Vaccine Market Size by Application
9.2.1 Latin America Inactivated Influenza Vaccine Sales by Application (2017-2028)
9.2.2 Latin America Inactivated Influenza Vaccine Revenue by Application (2017-2028)
9.3 Latin America Inactivated Influenza Vaccine Market Size by Country
9.3.1 Latin America Inactivated Influenza Vaccine Sales by Country (2017-2028)
9.3.2 Latin America Inactivated Influenza Vaccine Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Inactivated Influenza Vaccine Market Size by Type
10.1.1 Middle East and Africa Inactivated Influenza Vaccine Sales by Type (2017-2028)
10.1.2 Middle East and Africa Inactivated Influenza Vaccine Revenue by Type (2017-2028)
10.2 Middle East and Africa Inactivated Influenza Vaccine Market Size by Application
10.2.1 Middle East and Africa Inactivated Influenza Vaccine Sales by Application (2017-2028)
10.2.2 Middle East and Africa Inactivated Influenza Vaccine Revenue by Application (2017-2028)
10.3 Middle East and Africa Inactivated Influenza Vaccine Market Size by Country
10.3.1 Middle East and Africa Inactivated Influenza Vaccine Sales by Country (2017-2028)
10.3.2 Middle East and Africa Inactivated Influenza Vaccine Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 CSL Limited
11.1.1 CSL Limited Corporation Information
11.1.2 CSL Limited Overview
11.1.3 CSL Limited Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 CSL Limited Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 CSL Limited Recent Developments
11.2 GSK
11.2.1 GSK Corporation Information
11.2.2 GSK Overview
11.2.3 GSK Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 GSK Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 GSK Recent Developments
11.3 Sanofi Pasteur
11.3.1 Sanofi Pasteur Corporation Information
11.3.2 Sanofi Pasteur Overview
11.3.3 Sanofi Pasteur Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Sanofi Pasteur Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Sanofi Pasteur Recent Developments
11.4 Viatris
11.4.1 Viatris Corporation Information
11.4.2 Viatris Overview
11.4.3 Viatris Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Viatris Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Viatris Recent Developments
11.5 Hualan Biological
11.5.1 Hualan Biological Corporation Information
11.5.2 Hualan Biological Overview
11.5.3 Hualan Biological Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Hualan Biological Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Hualan Biological Recent Developments
11.6 AstraZeneca
11.6.1 AstraZeneca Corporation Information
11.6.2 AstraZeneca Overview
11.6.3 AstraZeneca Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 AstraZeneca Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 AstraZeneca Recent Developments
11.7 Sinovac Biotech
11.7.1 Sinovac Biotech Corporation Information
11.7.2 Sinovac Biotech Overview
11.7.3 Sinovac Biotech Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Sinovac Biotech Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Sinovac Biotech Recent Developments
11.8 Aleph Biomedical
11.8.1 Aleph Biomedical Corporation Information
11.8.2 Aleph Biomedical Overview
11.8.3 Aleph Biomedical Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Aleph Biomedical Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Aleph Biomedical Recent Developments
11.9 Abbott Laboratories
11.9.1 Abbott Laboratories Corporation Information
11.9.2 Abbott Laboratories Overview
11.9.3 Abbott Laboratories Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Abbott Laboratories Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Abbott Laboratories Recent Developments
11.10 Novartis International
11.10.1 Novartis International Corporation Information
11.10.2 Novartis International Overview
11.10.3 Novartis International Inactivated Influenza Vaccine Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Novartis International Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Novartis International Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Inactivated Influenza Vaccine Industry Chain Analysis
12.2 Inactivated Influenza Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Inactivated Influenza Vaccine Production Mode & Process
12.4 Inactivated Influenza Vaccine Sales and Marketing
12.4.1 Inactivated Influenza Vaccine Sales Channels
12.4.2 Inactivated Influenza Vaccine Distributors
12.5 Inactivated Influenza Vaccine Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Inactivated Influenza Vaccine Industry Trends
13.2 Inactivated Influenza Vaccine Market Drivers
13.3 Inactivated Influenza Vaccine Market Challenges
13.4 Inactivated Influenza Vaccine Market Restraints
14 Key Findings in The Global Inactivated Influenza Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Inactivated Influenza Vaccine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Trivalent Influenza Vaccine
Table 3. Major Manufacturers of Quadrivalent Influenza Vaccine
Table 4. Global Inactivated Influenza Vaccine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 5. Global Inactivated Influenza Vaccine Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Inactivated Influenza Vaccine Sales by Region (2017-2022) & (K Units)
Table 7. Global Inactivated Influenza Vaccine Sales Market Share by Region (2017-2022)
Table 8. Global Inactivated Influenza Vaccine Sales by Region (2023-2028) & (K Units)
Table 9. Global Inactivated Influenza Vaccine Sales Market Share by Region (2023-2028)
Table 10. Global Inactivated Influenza Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 11. Global Inactivated Influenza Vaccine Revenue Market Share by Region (2017-2022)
Table 12. Global Inactivated Influenza Vaccine Revenue by Region (2023-2028) & (US$ Million)
Table 13. Global Inactivated Influenza Vaccine Revenue Market Share by Region (2023-2028)
Table 14. Global Inactivated Influenza Vaccine Sales by Manufacturers (2017-2022) & (K Units)
Table 15. Global Inactivated Influenza Vaccine Sales Share by Manufacturers (2017-2022)
Table 16. Global Inactivated Influenza Vaccine Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 17. Global Inactivated Influenza Vaccine Revenue Share by Manufacturers (2017-2022)
Table 18. Inactivated Influenza Vaccine Price by Manufacturers (2017-2022) &(US$/Unit)
Table 19. Global Inactivated Influenza Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 20. Global Inactivated Influenza Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inactivated Influenza Vaccine as of 2021)
Table 21. Inactivated Influenza Vaccine Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Inactivated Influenza Vaccine Product Offered
Table 23. Date of Manufacturers Enter into Inactivated Influenza Vaccine Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Inactivated Influenza Vaccine Sales by Type (2017-2022) & (K Units)
Table 26. Global Inactivated Influenza Vaccine Sales by Type (2023-2028) & (K Units)
Table 27. Global Inactivated Influenza Vaccine Sales Share by Type (2017-2022)
Table 28. Global Inactivated Influenza Vaccine Sales Share by Type (2023-2028)
Table 29. Global Inactivated Influenza Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 30. Global Inactivated Influenza Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 31. Global Inactivated Influenza Vaccine Revenue Share by Type (2017-2022)
Table 32. Global Inactivated Influenza Vaccine Revenue Share by Type (2023-2028)
Table 33. Inactivated Influenza Vaccine Price by Type (2017-2022) & (US$/Unit)
Table 34. Global Inactivated Influenza Vaccine Price Forecast by Type (2023-2028) & (US$/Unit)
Table 35. Global Inactivated Influenza Vaccine Sales by Application (2017-2022) & (K Units)
Table 36. Global Inactivated Influenza Vaccine Sales by Application (2023-2028) & (K Units)
Table 37. Global Inactivated Influenza Vaccine Sales Share by Application (2017-2022)
Table 38. Global Inactivated Influenza Vaccine Sales Share by Application (2023-2028)
Table 39. Global Inactivated Influenza Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 40. Global Inactivated Influenza Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 41. Global Inactivated Influenza Vaccine Revenue Share by Application (2017-2022)
Table 42. Global Inactivated Influenza Vaccine Revenue Share by Application (2023-2028)
Table 43. Inactivated Influenza Vaccine Price by Application (2017-2022) & (US$/Unit)
Table 44. Global Inactivated Influenza Vaccine Price Forecast by Application (2023-2028) & (US$/Unit)
Table 45. North America Inactivated Influenza Vaccine Sales by Type (2017-2022) & (K Units)
Table 46. North America Inactivated Influenza Vaccine Sales by Type (2023-2028) & (K Units)
Table 47. North America Inactivated Influenza Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 48. North America Inactivated Influenza Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 49. North America Inactivated Influenza Vaccine Sales by Application (2017-2022) & (K Units)
Table 50. North America Inactivated Influenza Vaccine Sales by Application (2023-2028) & (K Units)
Table 51. North America Inactivated Influenza Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 52. North America Inactivated Influenza Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 53. North America Inactivated Influenza Vaccine Sales by Country (2017-2022) & (K Units)
Table 54. North America Inactivated Influenza Vaccine Sales by Country (2023-2028) & (K Units)
Table 55. North America Inactivated Influenza Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 56. North America Inactivated Influenza Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 57. Europe Inactivated Influenza Vaccine Sales by Type (2017-2022) & (K Units)
Table 58. Europe Inactivated Influenza Vaccine Sales by Type (2023-2028) & (K Units)
Table 59. Europe Inactivated Influenza Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 60. Europe Inactivated Influenza Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 61. Europe Inactivated Influenza Vaccine Sales by Application (2017-2022) & (K Units)
Table 62. Europe Inactivated Influenza Vaccine Sales by Application (2023-2028) & (K Units)
Table 63. Europe Inactivated Influenza Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 64. Europe Inactivated Influenza Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 65. Europe Inactivated Influenza Vaccine Sales by Country (2017-2022) & (K Units)
Table 66. Europe Inactivated Influenza Vaccine Sales by Country (2023-2028) & (K Units)
Table 67. Europe Inactivated Influenza Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 68. Europe Inactivated Influenza Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 69. Asia Pacific Inactivated Influenza Vaccine Sales by Type (2017-2022) & (K Units)
Table 70. Asia Pacific Inactivated Influenza Vaccine Sales by Type (2023-2028) & (K Units)
Table 71. Asia Pacific Inactivated Influenza Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 72. Asia Pacific Inactivated Influenza Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 73. Asia Pacific Inactivated Influenza Vaccine Sales by Application (2017-2022) & (K Units)
Table 74. Asia Pacific Inactivated Influenza Vaccine Sales by Application (2023-2028) & (K Units)
Table 75. Asia Pacific Inactivated Influenza Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 76. Asia Pacific Inactivated Influenza Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 77. Asia Pacific Inactivated Influenza Vaccine Sales by Region (2017-2022) & (K Units)
Table 78. Asia Pacific Inactivated Influenza Vaccine Sales by Region (2023-2028) & (K Units)
Table 79. Asia Pacific Inactivated Influenza Vaccine Revenue by Region (2017-2022) & (US$ Million)
Table 80. Asia Pacific Inactivated Influenza Vaccine Revenue by Region (2023-2028) & (US$ Million)
Table 81. Latin America Inactivated Influenza Vaccine Sales by Type (2017-2022) & (K Units)
Table 82. Latin America Inactivated Influenza Vaccine Sales by Type (2023-2028) & (K Units)
Table 83. Latin America Inactivated Influenza Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 84. Latin America Inactivated Influenza Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 85. Latin America Inactivated Influenza Vaccine Sales by Application (2017-2022) & (K Units)
Table 86. Latin America Inactivated Influenza Vaccine Sales by Application (2023-2028) & (K Units)
Table 87. Latin America Inactivated Influenza Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 88. Latin America Inactivated Influenza Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 89. Latin America Inactivated Influenza Vaccine Sales by Country (2017-2022) & (K Units)
Table 90. Latin America Inactivated Influenza Vaccine Sales by Country (2023-2028) & (K Units)
Table 91. Latin America Inactivated Influenza Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 92. Latin America Inactivated Influenza Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 93. Middle East and Africa Inactivated Influenza Vaccine Sales by Type (2017-2022) & (K Units)
Table 94. Middle East and Africa Inactivated Influenza Vaccine Sales by Type (2023-2028) & (K Units)
Table 95. Middle East and Africa Inactivated Influenza Vaccine Revenue by Type (2017-2022) & (US$ Million)
Table 96. Middle East and Africa Inactivated Influenza Vaccine Revenue by Type (2023-2028) & (US$ Million)
Table 97. Middle East and Africa Inactivated Influenza Vaccine Sales by Application (2017-2022) & (K Units)
Table 98. Middle East and Africa Inactivated Influenza Vaccine Sales by Application (2023-2028) & (K Units)
Table 99. Middle East and Africa Inactivated Influenza Vaccine Revenue by Application (2017-2022) & (US$ Million)
Table 100. Middle East and Africa Inactivated Influenza Vaccine Revenue by Application (2023-2028) & (US$ Million)
Table 101. Middle East and Africa Inactivated Influenza Vaccine Sales by Country (2017-2022) & (K Units)
Table 102. Middle East and Africa Inactivated Influenza Vaccine Sales by Country (2023-2028) & (K Units)
Table 103. Middle East and Africa Inactivated Influenza Vaccine Revenue by Country (2017-2022) & (US$ Million)
Table 104. Middle East and Africa Inactivated Influenza Vaccine Revenue by Country (2023-2028) & (US$ Million)
Table 105. CSL Limited Corporation Information
Table 106. CSL Limited Description and Major Businesses
Table 107. CSL Limited Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 108. CSL Limited Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 109. CSL Limited Recent Developments
Table 110. GSK Corporation Information
Table 111. GSK Description and Major Businesses
Table 112. GSK Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 113. GSK Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 114. GSK Recent Developments
Table 115. Sanofi Pasteur Corporation Information
Table 116. Sanofi Pasteur Description and Major Businesses
Table 117. Sanofi Pasteur Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 118. Sanofi Pasteur Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 119. Sanofi Pasteur Recent Developments
Table 120. Viatris Corporation Information
Table 121. Viatris Description and Major Businesses
Table 122. Viatris Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 123. Viatris Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 124. Viatris Recent Developments
Table 125. Hualan Biological Corporation Information
Table 126. Hualan Biological Description and Major Businesses
Table 127. Hualan Biological Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 128. Hualan Biological Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 129. Hualan Biological Recent Developments
Table 130. AstraZeneca Corporation Information
Table 131. AstraZeneca Description and Major Businesses
Table 132. AstraZeneca Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 133. AstraZeneca Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 134. AstraZeneca Recent Developments
Table 135. Sinovac Biotech Corporation Information
Table 136. Sinovac Biotech Description and Major Businesses
Table 137. Sinovac Biotech Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 138. Sinovac Biotech Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 139. Sinovac Biotech Recent Developments
Table 140. Aleph Biomedical Corporation Information
Table 141. Aleph Biomedical Description and Major Businesses
Table 142. Aleph Biomedical Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 143. Aleph Biomedical Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 144. Aleph Biomedical Recent Developments
Table 145. Abbott Laboratories Corporation Information
Table 146. Abbott Laboratories Description and Major Businesses
Table 147. Abbott Laboratories Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 148. Abbott Laboratories Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 149. Abbott Laboratories Recent Developments
Table 150. Novartis International Corporation Information
Table 151. Novartis International Description and Major Businesses
Table 152. Novartis International Inactivated Influenza Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 153. Novartis International Inactivated Influenza Vaccine Product Model Numbers, Pictures, Descriptions and Specifications
Table 154. Novartis International Recent Developments
Table 155. Key Raw Materials Lists
Table 156. Raw Materials Key Suppliers Lists
Table 157. Inactivated Influenza Vaccine Distributors List
Table 158. Inactivated Influenza Vaccine Customers List
Table 159. Inactivated Influenza Vaccine Market Trends
Table 160. Inactivated Influenza Vaccine Market Drivers
Table 161. Inactivated Influenza Vaccine Market Challenges
Table 162. Inactivated Influenza Vaccine Market Restraints
Table 163. Research Programs/Design for This Report
Table 164. Key Data Information from Secondary Sources
Table 165. Key Data Information from Primary Sources
List of Figures
Figure 1. Inactivated Influenza Vaccine Product Picture
Figure 3. Global Inactivated Influenza Vaccine Market Share by Type in 2021 & 2028
Figure 3. Trivalent Influenza Vaccine Product Picture
Figure 4. Quadrivalent Influenza Vaccine Product Picture
Figure 5. Global Inactivated Influenza Vaccine Market Share by Application in 2021 & 2028
Figure 6. Children
Figure 7. Adolescence
Figure 8. Adults
Figure 9. Elderly
Figure 10. Inactivated Influenza Vaccine Report Years Considered
Figure 11. Global Inactivated Influenza Vaccine Sales 2017-2028 (K Units)
Figure 12. Global Inactivated Influenza Vaccine Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Inactivated Influenza Vaccine Revenue 2017-2028 (US$ Million)
Figure 14. Global Inactivated Influenza Vaccine Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 15. Global Inactivated Influenza Vaccine Sales Market Share by Region (2017-2022)
Figure 16. Global Inactivated Influenza Vaccine Sales Market Share by Region (2023-2028)
Figure 17. North America Inactivated Influenza Vaccine Sales YoY (2017-2028) & (K Units)
Figure 18. North America Inactivated Influenza Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 19. Europe Inactivated Influenza Vaccine Sales YoY (2017-2028) & (K Units)
Figure 20. Europe Inactivated Influenza Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Asia-Pacific Inactivated Influenza Vaccine Sales YoY (2017-2028) & (K Units)
Figure 22. Asia-Pacific Inactivated Influenza Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Latin America Inactivated Influenza Vaccine Sales YoY (2017-2028) & (K Units)
Figure 24. Latin America Inactivated Influenza Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Middle East & Africa Inactivated Influenza Vaccine Sales YoY (2017-2028) & (K Units)
Figure 26. Middle East & Africa Inactivated Influenza Vaccine Revenue YoY (2017-2028) & (US$ Million)
Figure 27. The Inactivated Influenza Vaccine Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 28. The Top 5 and 10 Largest Manufacturers of Inactivated Influenza Vaccine in the World: Market Share by Inactivated Influenza Vaccine Revenue in 2021
Figure 29. Global Inactivated Influenza Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 30. Global Inactivated Influenza Vaccine Sales Market Share by Type (2017-2028)
Figure 31. Global Inactivated Influenza Vaccine Revenue Market Share by Type (2017-2028)
Figure 32. Global Inactivated Influenza Vaccine Sales Market Share by Application (2017-2028)
Figure 33. Global Inactivated Influenza Vaccine Revenue Market Share by Application (2017-2028)
Figure 34. North America Inactivated Influenza Vaccine Sales Market Share by Type (2017-2028)
Figure 35. North America Inactivated Influenza Vaccine Revenue Market Share by Type (2017-2028)
Figure 36. North America Inactivated Influenza Vaccine Sales Market Share by Application (2017-2028)
Figure 37. North America Inactivated Influenza Vaccine Revenue Market Share by Application (2017-2028)
Figure 38. North America Inactivated Influenza Vaccine Sales Share by Country (2017-2028)
Figure 39. North America Inactivated Influenza Vaccine Revenue Share by Country (2017-2028)
Figure 40. United States Inactivated Influenza Vaccine Revenue (2017-2028) & (US$ Million)
Figure 41. Canada Inactivated Influenza Vaccine Revenue (2017-2028) & (US$ Million)
Figure 42. Europe Inactivated Influenza Vaccine Sales Market Share by Type (2017-2028)
Figure 43. Europe Inactivated Influenza Vaccine Revenue Market Share by Type (2017-2028)
Figure 44. Europe Inactivated Influenza Vaccine Sales Market Share by Application (2017-2028)
Figure 45. Europe Inactivated Influenza Vaccine Revenue Market Share by Application (2017-2028)
Figure 46. Europe Inactivated Influenza Vaccine Sales Share by Country (2017-2028)
Figure 47. Europe Inactivated Influenza Vaccine Revenue Share by Country (2017-2028)
Figure 48. Germany Inactivated Influenza Vaccine Revenue (2017-2028) & (US$ Million)
Figure 49. France Inactivated Influenza Vaccine Revenue (2017-2028) & (US$ Million)
Figure 50. U.K. Inactivated Influenza Vaccine Revenue (2017-2028) & (US$ Million)
Figure 51. Italy Inactivated Influenza Vaccine Revenue (2017-2028) & (US$ Million)
Figure 52. Russia Inactivated Influenza Vaccine Revenue (2017-2028) & (US$ Million)
Figure 53. Asia Pacific Inactivated Influenza Vaccine Sales Market Share by Type (2017-2028)
Figure 54. Asia Pacific Inactivated Influenza Vaccine Revenue Market Share by Type (2017-2028)
Figure 55. Asia Pacific Inactivated Influenza Vaccine Sales Market Share by Application (2017-2028)
Figure 56. Asia Pacific Inactivated Influenza Vaccine Revenue Market Share by Application (2017-2028)
Figure 57. Asia Pacific Inactivated Influenza Vaccine Sales Share by Region (2017-2028)
Figure 58. Asia Pacific Inactivated Influenza Vaccine Revenue Share by Region (2017-2028)
Figure 59. China Inactivated Influenza Vaccine Revenue (2017-2028) & (US$ Million)
Figure 60. Japan Inactivated Influenza Vaccine Revenue (2017-2028) & (US$ Million)
Figure 61. South Korea Inactivated Influenza Vaccine Revenue (2017-2028) & (US$ Million)
Figure 62. India Inactivated Influenza Vaccine Revenue (2017-2028) & (US$ Million)
Figure 63. Australia Inactivated Influenza Vaccine Revenue (2017-2028) & (US$ Million)
Figure 64. China Taiwan Inactivated Influenza Vaccine Revenue (2017-2028) & (US$ Million)
Figure 65. Indonesia Inactivated Influenza Vaccine Revenue (2017-2028) & (US$ Million)
Figure 66. Thailand Inactivated Influenza Vaccine Revenue (2017-2028) & (US$ Million)
Figure 67. Malaysia Inactivated Influenza Vaccine Revenue (2017-2028) & (US$ Million)
Figure 68. Latin America Inactivated Influenza Vaccine Sales Market Share by Type (2017-2028)
Figure 69. Latin America Inactivated Influenza Vaccine Revenue Market Share by Type (2017-2028)
Figure 70. Latin America Inactivated Influenza Vaccine Sales Market Share by Application (2017-2028)
Figure 71. Latin America Inactivated Influenza Vaccine Revenue Market Share by Application (2017-2028)
Figure 72. Latin America Inactivated Influenza Vaccine Sales Share by Country (2017-2028)
Figure 73. Latin America Inactivated Influenza Vaccine Revenue Share by Country (2017-2028)
Figure 74. Mexico Inactivated Influenza Vaccine Revenue (2017-2028) & (US$ Million)
Figure 75. Brazil Inactivated Influenza Vaccine Revenue (2017-2028) & (US$ Million)
Figure 76. Argentina Inactivated Influenza Vaccine Revenue (2017-2028) & (US$ Million)
Figure 77. Colombia Inactivated Influenza Vaccine Revenue (2017-2028) & (US$ Million)
Figure 78. Middle East and Africa Inactivated Influenza Vaccine Sales Market Share by Type (2017-2028)
Figure 79. Middle East and Africa Inactivated Influenza Vaccine Revenue Market Share by Type (2017-2028)
Figure 80. Middle East and Africa Inactivated Influenza Vaccine Sales Market Share by Application (2017-2028)
Figure 81. Middle East and Africa Inactivated Influenza Vaccine Revenue Market Share by Application (2017-2028)
Figure 82. Middle East and Africa Inactivated Influenza Vaccine Sales Share by Country (2017-2028)
Figure 83. Middle East and Africa Inactivated Influenza Vaccine Revenue Share by Country (2017-2028)
Figure 84. Turkey Inactivated Influenza Vaccine Revenue (2017-2028) & (US$ Million)
Figure 85. Saudi Arabia Inactivated Influenza Vaccine Revenue (2017-2028) & (US$ Million)
Figure 86. UAE Inactivated Influenza Vaccine Revenue (2017-2028) & (US$ Million)
Figure 87. Inactivated Influenza Vaccine Value Chain
Figure 88. Inactivated Influenza Vaccine Production Process
Figure 89. Channels of Distribution
Figure 90. Distributors Profiles
Figure 91. Bottom-up and Top-down Approaches for This Report
Figure 92. Data Triangulation
Figure 93. Key Executives Interviewed

---